ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

News

June 27, 2018 DemoDay at La Salle Technova

We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates.

https://twitter.com...

June 20, 2018 Investment Forum from ACCIÓ 2018

Finalists in the Investment Forum from ACCIÓ 2018!

http://www.accio.gencat.cat...




Investment Forum from ACCIÓ 2018
May 31, 2018 IE Venture Network Area 31

We have assisted to the IE Venture Network Area 31 in Madrid.

https://entrepreneurship.blogs.ie.edu...

May 15, 2018 MedTeX

ADmit Therapeutics selected in the MedTeX programme organized by Barcelona Scientific Park.

http://www.pcb.ub.edu...

Apr. 25, 2018 Lab4Health

ADmit Therapeutics is one of five start ups selected to participate in the Lab4Health in the social impact accelerator Ship2B.

https://www.ship2b.org...
https://twitter.com/Ship2B...
Jan. 30, 2018 We are seeking private investment to obtain the CE mark

The new EU IVD Regulation has finally been adopted on April 5th 2017 and ADmit Therapeutics has already drawn the development plan according to this new Regulation.

Dec. 21, 2017 ADmit Therapeutics S.L. was created

ADmit Therapeutics has been created, acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early AD detection.

This website uses cookies, both our own and third party cookies, to improve your online experience and collect statistical information on browsing patterns.
By continuing to use this website, you consent cookies being installed on your browser. More information on our Cookies Policy